Integrated genomics of ovarian xenograft tumor progression and chemotherapy response

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Stuckey, Ashley ^a   Fischer, Andrew ^b   Miller, Daniel H ^b   Hillenmeyer, Sara ^b   Kim, Kyu K ^a   Ritz, Anna ^c   Singh, Rakesh K ^a   Raphael, Benjamin J ^c   Brard, Laurent ^d   Brodsky, Alexander S ^b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c Brown Univerity   (United States)

^d SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MT 19C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; UNCLASSIFIED DRUG; VITAMIN D DERIVATIVE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; ERGOCALCIFEROL; MT19C COMPOUND; TRANSCRIPTOME; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE REGULATION; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA DEGRADATION; DNA REPAIR; DOWN REGULATION; DRUG RESPONSE; ENERGY METABOLISM; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENOMICS; MOUSE; NONHUMAN; OVARY CANCER; RIBOSOME; TRANSLATION REGULATION; TUMOR GROWTH; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CHEMISTRY; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG EFFECT; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; METHODOLOGY; NUDE MOUSE; OVARY TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLUSTER ANALYSIS; ERGOCALCIFEROLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMICS; HUMANS; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PPAR GAMMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THIAZOLIDINEDIONES; TRANSCRIPTOME; TUMOR BURDEN; VITAMINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960561551     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-308     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010, 18287387.
2. Kikkawa F, Nawa A, Ino K, Shibata K, Kajiyama H, Nomura S. Advances in treatment of epithelial ovarian cancer. Nagoya J Med Sci 2006, 68(1-2):19-26.
3. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007, 7(9):684-700. 10.1038/nrc2196, 17721433.
4. Lange TS, Stuckey AR, Robison K, Kim KK, Singh RK, Raker CA, Brard L. Effect of a Vitamin D(3) derivative (B3CD) with postulated anti-cancer activity in an ovarian cancer animal model. Invest New Drugs 2009, 28(5):543-553.
5. Lange TS, Zou Y, Singh RK, Kim KK, Kristjansdottir K, Sholler GL, Brard L. Chemotherapeutic Effect of Calcidiol Derivative B3CD in a Neuroblastoma Xenograft Model. Chem Biol Drug Des 2010, 76(2):164-173. 10.1111/j.1747-0285.2010.00988.x, 20492445.
6. Shackleton M, Quintana E, Fearon ER, Morrison SJ. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell 2009, 138(5):822-829. 10.1016/j.cell.2009.08.017, 19737509.
7. Oliver TG, Mercer KL, Sayles LC, Burke JR, Mendus D, Lovejoy KS, Cheng MH, Subramanian A, Mu D, Powers S, et al. Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev 2010, 24(8):837-852. 10.1101/gad.1897010, 2854397, 20395368.
8. Gorringe KL, Campbell IG. Large-scale genomic analysis of ovarian carcinomas. Mol Oncol 2009, 3(2):157-164. 10.1016/j.molonc.2008.12.005, 19383377.
9. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010, 463(7283):899-905. 10.1038/nature08822, 2826709, 20164920.
10. Bignell GR, Greenman CD, Davies H, Butler AP, Edkins S, Andrews JM, Buck G, Chen L, Beare D, Latimer C, et al. Signatures of mutation and selection in the cancer genome. Nature 2010, 463(7283):893-898. 10.1038/nature08768, 20164919.
11. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci USA 2002, 99(20):12963-12968. 10.1073/pnas.162471999, 130569, 12297621.
12. Andrews J, Kennette W, Pilon J, Hodgson A, Tuck AB, Chambers AF, Rodenhiser DI. Multi-platform whole-genome microarray analyses refine the epigenetic signature of breast cancer metastasis with gene expression and copy number. PLoS One 2010, 5(1):e8665.. 2801616, 20084286.
13. Brard L, Lange TS, Robinson K, Kim KK, Brodsky AS, Uzun A, Padbury J, Moore R, Singh RK. Discovery of the first Ergocalciferol derived vitamin D receptor independent true non-hypercalcemic anti-cancer agent (MT19c). submitted 2010,
14. Venkatraman ES, Olshen AB. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 2007, 23(6):657-663. 10.1093/bioinformatics/btl646, 17234643.
15. Brard L, Robison K, Singh R, Kim K, Lange. A Novel Non-Hypercalcemic Vitamin D Derivative in the Treatment of Ovarian Cancer. Building Interdisciplinary Research Careers in Women's Health (BIRCWH): 2007 2007, 1095-1107.
16. Robison K, Kim K, Singh R, Lange T, Granai C, Brard L. The use of a vitamin D derivative in a mouse xenograft ovarian cancer model. GOG: 2008 2008, S68.
17. Bronson MW, Hillenmeyer S, Park RW, Brodsky AS. Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells. Mol Endocrinol 2010, 24(6):1120-1135. 10.1210/me.2009-0436, 2875799, 20392875.
18. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005, 102(43):15545-15550. 10.1073/pnas.0506580102, 1239896, 16199517.
19. Payton M, Coats S. Cyclin E2, the cycle continues. Int J Biochem Cell Biol 2002, 34(4):315-320. 10.1016/S1357-2725(01)00137-6, 11854029.
20. Chen HZ, Tsai SY, Leone G. Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat Rev Cancer 2009, 9(11):785-797. 10.1038/nrc2696, 19851314.
21. Majumder S. REST in good times and bad: roles in tumor suppressor and oncogenic activities. Cell Cycle 2006, 5(17):1929-1935. 10.4161/cc.5.17.2982, 16929174.
22. Mishra P, Gulbake A, Jain A, Khare P, Soni V, Vyas SP, Jain SK. Steroid receptors as molecular targets for cancer diagnosis and therapy. Crit Rev Ther Drug Carrier Syst 2009, 26(3):207-273.
23. Wiench M, Hager GL. Expanding horizons for nuclear receptors. EMBO Rep 2010, 11(8):569-571. 10.1038/embor.2010.111, 20634803.
24. Girnun GD, Naseri E, Vafai SB, Qu L, Szwaya JD, Bronson R, Alberta JA, Spiegelman BM. Synergy between PPARgamma ligands and platinum-based drugs in cancer. Cancer Cell 2007, 11(5):395-406. 10.1016/j.ccr.2007.02.025, 2564847, 17482130.
25. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010, 24(15):1580-1589. 10.1101/gad.1941710, 2912554, 20679392.
26. The data was obtained from the Wellcome Trust Sanger Institute Cancer Genome Project web site. , http://www.sanger.ac.uk/genetics/CGP
27. Gordon AN, Finkler N, Edwards RP, Garcia AA, Crozier M, Irwin DH, Barrett E. Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study. Int J Gynecol Cancer 2005, 15(5):785-792. 10.1111/j.1525-1438.2005.00137.x, 16174225.
28. Secord AA, Blessing JA, Armstrong DK, Rodgers WH, Miner Z, Barnes MN, Lewandowski G, Mannel RS. Phase II trial of cetuximab and carboplatin in relapsed platinum-sensitive ovarian cancer and evaluation of epidermal growth factor receptor expression: a Gynecologic Oncology Group study. Gynecol Oncol 2008, 108(3):493-499. 10.1016/j.ygyno.2007.11.029, 2744339, 18191993.
29. Sood AK, Armaiz-Pena GN, Halder J, Nick AM, Stone RL, Hu W, Carroll AR, Spannuth WA, Deavers MT, Allen JK, et al. Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest 2010, 120(5):1515-1523. 10.1172/JCI40802, 2860925, 20389021.
30. Garson K, Shaw TJ, Clark KV, Yao DS, Vanderhyden BC. Models of ovarian cancer--are we there yet?. Mol Cell Endocrinol 2005, 239(1-2):15-26. 10.1016/j.mce.2005.03.019, 15955618.
31. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, Kuo WL, Gwadry F, Ajay, Kouros-Mehr H, Fridlyand J, et al. Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 2006, 5(4):853-867. 10.1158/1535-7163.MCT-05-0155, 2733874, 16648555.
32. Chin L, Gray JW. Translating insights from the cancer genome into clinical practice. Nature 2008, 452(7187):553-563. 10.1038/nature06914, 2730524, 18385729.